Traditional markers of cardiac toxicity fail to detect marked reductions in cardioresriratory fitness among cancer patients undergoing anti-cancer treatment
Erin J Howden, Steve Foulkes, Hayley T Dillon, Ashley Bigaran, Leah Wright, Kristel Janssens, Prue Comie, Benedict Costello, Andre La Gerche
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING | OXFORD UNIV PRESS | Published : 2021
AIMS: Left ventricular ejection fraction (LVEF) is standard of care for evaluating chemotherapy-associated cardiotoxicity, although global longitudinal strain (GLS) offers advantages. However, neither change in LVEF or GLS has been associated with short-term symptoms, functional capacity, or long-term heart failure (HF) risk. We sought to determine whether an integrative measure of cardiovascular function (VO2peak) that is strongly associated with HF risk would be more sensitive to cardiac damage induced by cancer treatment than LVEF, GLS, or cardiac biomarkers. METHODS AND RESULTS: Patients (n = 206, 53 ± 13 years, 35% male) scheduled to commence anti-cancer treatment completed assessment p..View full abstract
Awarded by World Cancer Research Fund
Awarded by Australian National Heart Foundation Future Leader Fellowships
The study is funded by two project grants from the World Cancer Research Fund (Reference number: 2019/1948 and 2018/1666). E.J.H. (102536) and A.L.G. (102021) are supported by the Australian National Heart Foundation Future Leader Fellowships.